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Capture Hi-C reveals novel candidate genes and
complex long-range interactions with related
autoimmune risk loci
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Genome-wide association studies have been tremendously successful in identifying genetic
variants associated with complex diseases. The majority of association signals are intergenic
and evidence is accumulating that a high proportion of signals lie in enhancer regions. We use
Capture Hi-C to investigate, for the ﬁrst time, the interactions between associated variants for
four autoimmune diseases and their functional targets in B- and T-cell lines. Here we report
numerous looping interactions and provide evidence that only a minority of interactions are
common to both B- and T-cell lines, suggesting interactions may be highly cell-type speciﬁc;
some disease-associated SNPs do not interact with the nearest gene but with more
compelling candidate genes (for example, FOXO1, AZI2) often situated several megabases
away; and ﬁnally, regions associated with different autoimmune diseases interact with each
other and the same promoter suggesting common autoimmune gene targets (for example,
PTPRC, DEXI and ZFP36L1).
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T
he idenﬁcation of the precise gene targets of variants
associated with complex traits detected through genome-
wide association studies (GWAS) has proved challenging1
but is essential if the full potential of genetic studies is to be
realised. Accumulating evidence suggests the majority of these
variants lie outside traditional protein-coding genes and are
enriched in enhancer regions, which are both cell-type and
stimulus speciﬁc2–4. The task now is to identify which genes are
implicated and understand which cell types are involved, to
ascertain the biological pathways that are perturbed in individuals
who are genetically susceptible to disease. It is well-established
that enhancers regulate gene transcription by physical
interactions5. These can operate over large genetic distances, so
the tradition of annotating GWAS hits with the closest, or most
biologically plausible gene candidate, may prove misleading and
result in expensive, time consuming efforts to deﬁne the function
of non-causal genes.
The utility of chromosome conformation capture technology
(Capture Hi-C) to detect the patterns of interactions between
chromosomal regions has been demonstrated6–9. Here, for the
ﬁrst time, we used this approach to characterize the interactions
of conﬁrmed susceptibility loci for four autoimmune diseases:
rheumatoid arthritis (RA), type 1 diabetes (T1D), psoriatic
arthritis (PsA) and juvenile idiopathic arthritis (JIA) with the
aim of linking disease-associated SNPs with disease-causing
genes. Uniquely, we have tested the interactions in two
complementary experiments: ﬁrst, Region Capture targets
regions associated with disease10–14; second, Promoter Capture
provides independent validation through capturing all known
promoters within 500 kb of lead disease-associated single
nucleotide polymorphisms (SNPs). Our study expands on
recent applications of the Capture Hi-C method ﬁrstly, by
increasing the depth of sequencing and therefore the resolution,
(average 10,000 interactions per restriction fragment), second, by
comprehensively targeting the full known genetic component of
four related autoimmune diseases and ﬁnally by performing
complimentary experiments, such that we target the disease-
associated regions and, in separate experiments, all gene
promoters within 500 kb, so providing direct, independent,
reciprocal validation for each interaction. All experiments were
performed in human B (GM12878) and T (Jurkat) cell lines,
selected because they are most relevant to these diseases3.
Hi-C libraries were generated for both cell lines15, then
hybridized to custom biotinylated RNA baits and sequenced on
an Illumina HiSeq 2500. We tested for signiﬁcant interactions
using a negative binomial distribution as described previously6,
performing all experiments in duplicate.
Our ﬁndings provide compelling evidence that disease-
associated SNPs, currently nominally assigned to the closest
plausible gene candidate, may well-regulate genes some distance
away. We also show that in a subset of risk loci, SNPs associated
to different autoimmune diseases physically interact with and
may well-regulate the same genes but with differing enhancer
mechanisms. A number of the interactions also show evidence of
cell-type speciﬁcity, occurring in either the B- or T-cell lines only.
Results
Summary of identiﬁed interactions. Our unique study design
determined a complex array of interactions between
disease-associated regions and promoters (Fig. 1). After quality
control, in the Region Capture experiment, 60.9 million and
54.9 million unique di-tags (comprising one restriction fragment
from a capture target region and its ligated interacting partner)
were on-target for GM12878 and Jurkat cell lines, respectively
(average 21,170 reads per HindIII restriction fragment; 62%
capture efﬁciency). Similarly, in the Promoter Capture experi-
ment, 121.1 million (GM12878) and 115 million (Jurkat) unique
di-tags were on-target (average 21,448 reads per HindIII restric-
tion fragment; 70% capture efﬁciency) (Fig. 2).
At any given false discovery rate (FDR) threshold, interactions
are called with an unknown rate of false negatives. With the
assumption that interactions called in both the Region and
Promoter Capture experiments are more likely to be true positives
compared with those only seen in one experiment, we evaluated
several potential FDR thresholds (Fig. 3). We saw a consistent
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Figure 1 | A schematic of a hypothetical associated region including possible chromatin interactions. Chromatin interactions are shown by arcs, those
above the promoter capture target region are observed in the ‘Region Capture’ experiment; those below are observed in the ‘Promoter Capture’ experiment.
All potential chromatin interactions are shown and are coloured by their potential to appear and be validated in both capture experiments. Those in green
are observed in both the ‘Region Capture’ and the ‘Promoter Capture’ and comprise the ‘conﬁrmed’ interaction set. Interactions shown in purple are only
present in one capture experiment and were therefore not validated. Other interactions (red, orange and blue) would only be observed in either the ‘Region
Capture’ or ‘Promoter Capture’ and could therefore not be validated as described. The inset shows a magniﬁed view of the associated region (as deﬁned by
LD) detailing which restriction fragments were targeted in the ‘Region Capture’ and which were excluded as they appeared in the ‘Promoter Capture’.
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enrichment in interactions called in both experiments at decreasing
Promoter Capture experiment FDR thresholds, providing
conﬁdence that they represent true interactions. At 5% FDR, we
called 8,594 interactions in the Region Capture experiment
representing 764 targeted HindIII restriction fragments. Of these
interactions 372/8,594 (4.3%) from 116 targeted HindIII restriction
fragments demonstrated evidence of interacting with a promoter
within 500 kb, and so could be validated by the complementary
capture method. Of these, 146/342 interactions were identiﬁed in
the Promoter Capture experiment (Fig. 2), implicating 29 regions,
of which 15 contain disease-associated SNPs (Supplementary
Table 1). The majority of signiﬁcant interactions were cell-type
speciﬁc, with only 20% found in both cell lines.
We compared our data with publicly available chromatin
interaction data in similar cell lines and could detect the well-
established interactions with the cis-acting regulatory region of
the HBA locus16 (Supplementary Fig. 1a) and interactions in the
5C ENCODE (https://www.encodeproject.org/)17 experiments at
two regions: IFNAR1 and IL5 (Supplementary Fig. 1b,c).
Interactions with novel candidate genes. Conﬁrmed interactions
provided examples of disease-associated SNPs that do not interact
with the nearest gene, but rather with promoters some distance
away, implicating entirely different target genes. For example,
strong evidence was found to suggest that regions with SNPs
associated with RA, situated proximal to the EOMES gene, make
strong physical contact with the promoter of AZI2, a gene
involved in NFkB activation, some 640 kb away (Fig. 4a) in
both GM12878 and Jurkat cell lines. In addition, variants
associated with RA and JIA in the 30 intronic region of COG6, a
gene encoding a component of Golgi apparatus, show interactions
with the promoter of the FOXO1 gene, mapping over 1Mb away,
in both cell types (Fig. 4b). Recent ﬁndings suggest that the
FOXO1 gene is important in the survival of ﬁbroblast-like
synoviocytes (FLS) in RA18 and is hypermethylated in RA FLS
compared with osteoarthritis FLS19, providing strong supporting
functional evidence as to gene candidature.
Common interaction targets mediated by multiple genetic loci.
Perhaps the most striking ﬁnding comes from genetic regions that
harbour susceptibility loci for different autoimmune diseases,
where the lead disease-associated SNP for one disease maps some
distance from the lead disease-associated SNP for other
autoimmune diseases; previously, using the ‘nearest candidate
gene’ annotation method, different genes would have been
assigned to the diseases but our work shows that they may all act
on the same gene promoter. We provide three examples below to
illustrate the ﬁndings. First, the 16p13 region contains SNPs
associated with both T1D and multiple sclerosis that locate within
intron 19 of the CLEC16A gene. A physical interaction between a
20-kb region of CLEC16A and the promoter of DEXI has
previously been reported20, although was not detected in the
current study. Our data suggest that a separate, independent
region, associated with both T1D and JIA, near the RMI2 gene
and 530 kb from the DEXI gene, also interacts with the DEXI
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Figure 2 | Flowchart summarizing capture Hi-C experiments by cell line.
The ‘Region Capture’ experiment is shown on the left and the ‘Promoter
Capture’ experiment on the right. Flowchart sections are coloured by cell
type: light blue—GM12878 cells; light grey—Jurkat cells and grey—both cell
types. Each section label is shown in dark blue.
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Figure 3 | Fold enrichment. Fold enrichment of retained interactions called
in the promoter capture experiments with decreasing FDR thresholds, given
they had been called in the region capture experiments at the FDR
threshold shown. ‘—’ shows the enrichment found by focusing only on
interactions called in the region capture experiments for which the other
end lay in a HindIII restriction fragment targeted in the promoter capture
design.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10069 ARTICLE
NATURE COMMUNICATIONS | 6:10069 |DOI: 10.1038/ncomms10069 | www.nature.com/naturecommunications 3
promoter (Fig. 5a). Furthermore, a region proximal to the
ZC3H7A gene, associated with RA susceptibility, some 1.2Mb
from DEXI, interacts with both the T1D/JIA-associated region
and the DEXI promoter.
The second example is provided by RA-associated variants
mapping within a strong enhancer region intronic of RAD51B,
where a signiﬁcant interaction is observed with the promoter of
the ZFP36L1 gene. SNPs in the promoter region of ZFP36L1 are
independently associated with JIA but not RA; however, the
interaction of the ZFP36L1 promoter with the RA-associated
SNPs suggests that the causal gene in both diseases may be
ZFP36L1 and not RAD51B. ZFP36L1 is a zinc ﬁnger transcription
factor involved in the transition of B cells to plasma cells and it is
noteworthy that the interaction with the RA-associated region
was only seen in the B-cell line (Fig. 5b).
Finally we show evidence that SNPs associated with PsA within
the DENND1B gene make strong contact with a region associated
with RA within the PTPRC gene, which is responsible for T- and
B-cell receptor signalling and maps over 1Mb away (Fig. 5c).
We, like others8,9, have demonstrated a complex relationship
between promoters and enhancers, where promoters interact with
many enhancers and enhancers interact with many promoters,
rarely in a one-to-one relationship (Fig. 1 and Supplementary
Table 2). Enhancers containing risk variants for autoimmune
diseases can, therefore, ‘meet’ at the same promoters. This
challenges the assumption that disease-associated SNPs have to
be in close linkage disequilibrium (LD) to have a disease related
effect on the same gene. In addition, these ﬁndings may well-
suggest an evolutionary phylogeny, where polymorphic variants
regulating expression of the same gene result in either different
autoimmune diseases or different molecular mechanisms
resulting in risk of the same disease.
Interactions with previously implicated loci. Among the other
141 conﬁrmed interactions, we observed examples of disease-
associated SNPs within the 30 untranslated region, or within
introns of a gene, interacting with the promoter of the same gene
(STAT4, CDK6, Supplementary Fig. 2a,b); disease-associated
SNPs within lncRNA interacting with the promoter of genes
(RBPJ, Supplementary Fig. 3) and several examples of restriction
fragments, proximal to those containing disease-associated SNPs,
interacting with promoters some distance away (ARID5B, IL2RA,
TLE3, Supplementary Fig. 4a–c), supporting recent ﬁndings that
disease-associated SNPs are enriched outside transcription factor-
binding sites3.
Long-range interactions. Perhaps unexpectedly, B80% of
signiﬁcant interactions occurred at distances exceeding 500 kb
(Supplementary Fig. 5) and interacted with ‘non-promoters’,
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Figure 4 | Examples of chromatin interactions implicating novel gene candidates. (a) EOMES SNPs—both GM12878 and Jurkat cell lines show that SNPs
situated proximal to the EOMES gene interact with the promoter of AZI2I, involved in NFkB activation, situatedB640kb away. (b) COG6 SNPs—interactions
are shown that link SNPs within the COG6 to the FOXO1 promoter, over 1Mb away, in both cell types. Genomic co-ordinates are shown along the top of each
panel and tracks are labelled A–Y (empty tracks removed for clarity): (A) HindIII restriction fragments; (B–E) Regions targeted and restriction fragments
included in the region (B,C) and promoter (D,E) capture experiments; (F) RefSeq Genes from the UCSC Genome Browser, downloaded 1 January 2012; (G,I,K)
Index SNPs identiﬁed for RA (G), JIA (I) and PsA (K). Associations in red were identiﬁed in the RA Immunochip study. SNPs in blue were novel associations
identiﬁed in the RA trans-ethnic GWAS meta-analysis, JIA and PsA SNPs were identiﬁed in the JIA and PsA Immunochip studies; (H,J,L) Density plots showing
1000 Genomes SNPs in LD (r2Z0.8) with the index SNPs (green–red) for RA (H), JIA (J) and PsA (L); (M) T1D Credible set SNPs identiﬁed in the T1D
Immunochip study; (N–Q) Signiﬁcant Interactions identiﬁed in the region and promoter capture experiments in GM12878 (N,O) and Jurkat (P,Q) cells; (R–Y)
Data from the WashU Encode track hub showing DNaseI HS sites, H3K4me1 histone marks and H3K27ac histone marks for GM12878 (R,T,V) and CD3
Primary (S,U,W) cells and BROAD ChromHMM states for GM12878 (X) and CD4 Naive Primary cells (Y).
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reducing the number of interactions available for co-validation in
the Promoter and Region Capture experiments (targeted genes in
the Promoter Capture not extending that far) and reinforcing the
idea that GWAS regions may be involved with complex
long-range gene regulation possibly involving multiple enhancer
elements. To investigate whether these are likely to be true
interactions, we compared results from the largest Hi-C data set
on GM12878 cells reported, to date21. Of the 4,607 longer
distance interactions (4500 kb) we called at FDR o5% in our
data, 377 were found at 50 times observed over expected in
the independent Hi-C data set (Supplementary Data 1). This
provided both strong conﬁrmation of our long-range capture
Hi-C results we already co-validated with Promoter and Region
Capture (for example, FOXO1, ZFP36L1, Supplementary Fig. 6)
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Figure 5 | Examples of chromatin interactions linking several disease associations to a common promoter. (a) DEXI—both GM12878 and Jurkat cell
lines show that SNPs associated independently with RA, PsA and T1D interact with the DEXI promoter. In addition, evidence suggests that the RA and JIA
SNP regions interact in GM12878 cells. (b) RAD51B—RA associations located within a strong enhancer are shown to interact with the promoter of ZFP36L1,
a gene involved in B-cell transition, which also contains SNPs associated with JIA. (c), PTPRC—Variants associated with PsA, within the DENND1B are shown
to interact with PTPRC, a region independently associated with RA. Genomic co-ordinates are shown along the top of each panel and tracks are labelled
A—Y as in Fig. 4.
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and supports many potentially novel interactions (for example,
MMEL1, Supplementary Fig. 7), but detailed examination to
conﬁrm these long-range interactions is now required.
Discussion
Our targeted Capture Hi-C analyses have identiﬁed, for the ﬁrst
time, many long-range interactions between autoimmune risk
loci and their putative target genes. Using this methodology we
have intriguing data illustrating that regions associated with more
than one disease, often some distance apart, interact with the
same gene and that associated regions can ‘skip’ genes to interact
with more distant novel candidates. Our results provide new
insights into complex disease genetics and changes the way we
view the causal genes in disease, with obvious implications for
pathway analysis and identiﬁcation of therapeutic targets. Since
we uncovered evidence of cell-speciﬁc interactions, the current
study is likely to be only the beginning of similar explorations.
Further work to characterize functionally the observed interac-
tions, including eQTL studies using a range of cell types and
stimulatory conditions, are required to determine how disease-
associated SNPs inﬂuence the risk of disease, with the aim of
better understanding disease aetiology.
Methods
SNP and region associations. All independent lead disease-associated SNPs for
RA were selected from both the ﬁne-mapped Immunochip study10 and a trans-
ethnic GWAS meta-analysis11. Lead disease-associated SNPs were also added from
the Immunochip ﬁne mapping studies for JIA13 and PsA12. This resulted in a total
of 242 distinct variants associated with one or more of the three diseases after
exclusion of HLA-associated SNPs. Associated regions were deﬁned by selecting all
SNPs in LD with the lead disease-associated SNP (r24¼ 0.8; 1000 Genomes phase
1 EUR samples; May 2011). In addition to the SNP associations, credible SNP set
regions were deﬁned for both T1D- and RA-associated loci discovered by the
Immunochip array at a 99% conﬁdence level14. RA loci, as deﬁned from the
Immunochip analysis, were extended to include the credible SNP region where
necessary and overlapping regions were merged using the BEDTools v2.21.0
(ref. 22) merge command resulting in 211 associated regions.
Target enrichment design. To remain hypothesis free and to validate signiﬁcant
ﬁndings, two target enrichments were designed. The ﬁrst targeted the ‘associated
region’ and was called the ‘Region Capture’ set. The second targeted all known gene
promoters overlapping the region 500 kb up- and downstream of the lead disease-
associated SNP dubbed as the ‘Promoter Capture’ set. Capture oligos (120 bp;
25–65% GC, o3 unknown (N) bases) were designed using a custom Perl script
within 400 bp but as close as possible to each end of the targeted HindIII restriction
fragments and submitted to the Agilent eArray software (Agilent) for manufacture.
Region Capture design. Capture oligonucleotides were designed to all HindIII
restriction fragments in each previously deﬁned associated region after excluding
those already targeted in the Promoter Capture. Regions were extended by one
restriction fragment where there was o500 bp between the restriction site and the
region start/end. This resulted in 3,159 restriction fragments in total after merging
overlapping regions. Of these, 1,028 failed design, 1,096 had both ends captured
and 1,035 had one end captured, producing a target capture of 387.24 kb covering a
genomic region of 7.46Mb (3.5 kb/restriction fragment on average). In addition, a
control region, which represents a well-characterized region of long-range inter-
actions, was also included: HBA (174.57 kb genomic; 26 restriction fragments;
6.71 kb/restriction fragment).
Promoter Capture design. Promoter Capture target regions were deﬁned as
500 kb up- and downstream of each disease-associated SNP. These regions were
further extended to encompass the associated regions where appropriate. HindIII
restriction fragments were identiﬁed within 500 bp of the transcription start site of
all genes mapping to the deﬁned regions (Ensembl release 75; GRCh37) and
overlapping regions were merged using the BEDTools22 merge command resulting
in 6,296 restriction fragments. Of these, 792 failed design, 2,986 had both ends
captured and 2,518 had one end captured, producing a target capture of 1.02Mb.
The 5,504 captured restriction fragments covered a genomic region of 38.76Mb
(7.04 kb/restriction fragment on average) and contained promoters for 3,857 genes.
The HBA control region previously mentioned was also included.
Cell culture and crosslinking. The GM12878 B-lymphoblastoid cell line,
produced from the blood of a female donor with northern and western European
ancestry by EBV transformation, was obtained from Coriell Institute for Medical
Research. Lymphoblastoid cell lines were cultured in Roswell Park Memorial
Institute (RPMI) 1640 per 20mM L-glutamine supplemented with 15% foetal
bovine serum (FBS) in 25 cm2 vented culture ﬂasks at 37 C per 5% CO2. The
T-lymphoblastoid Jurkat E6.1 cell line, originating from the peripheral blood of a
14-year-old boy in the study by Schneider et al.23, was obtained from LGC
Standards and cultured in RPMI 1640 per 20mM L-glutamine supplemented with
10% FBS in 25 cm2 vented culture ﬂasks at 37 C/5% CO2. To generate Hi-C
libraries, 5–6 107 GM12878 and Jurkat cells were grown to B90% conﬂuence
then formaldehyde crosslinking was carried out as described in the study by Belton
et al.15. Cells were washed in Dulbecco’s Modiﬁed Eagle’s medium (DMEM)
without serum then crosslinked with 2% formaldehyde for 10min at room
temperature. The crosslinking reaction was quenched by adding cold 1M glycine to
a ﬁnal concentration of 0.125M for 5min at room temperature, followed by 15min
on ice. Crosslinked cells were washed in ice-cold PBS, the supernatant discarded
and the pellets ﬂash-frozen in liquid nitrogen and stored at  80 C.
Hi-C library generation. Cells were thawed on ice and re-suspended in 50ml
freshly prepared ice-cold lysis buffer (10mM Tris-HCl pH 8, 10mM NaCl, 0.2%
Igepal CA-630, one protease inhibitor cocktail tablet). Routinely, two pellets from
each cell line were re-suspended and combined in 7ml complete lysis buffer to give
B5-6 107 cells. Cells were lysed on ice for a total of 30min, with 2 10 strokes of
a Dounce homogeniser with a 5-min break between Douncing. Following lysis, the
nuclei were pelleted and washed with 1.25NEB Buffer 2 then re-suspended in
1.25NEB Buffer 2 to make aliquots of 5–6 106 cells for digestion. Following lysis,
Hi-C libraries were digested using HindIII then prepared as described in the study by
van Berkum et al.24 with modiﬁcations described in the study by Dryden et al.6.
Pre-Capture ampliﬁcation was performed with eight cycles of PCR on multiple
parallel reactions from Hi-C libraries immobilized on Streptavidin beads, which were
pooled post PCR and SPRI bead puriﬁed. The ﬁnal library was re-suspended in 30ml
TLE and the quality and quantity assessed by Bioanalyzer and qPCR.
Solution hybridization capture of Hi-C library. Hi-C samples corresponding to
750 ng were concentrated in a Speedvac then re-suspended in 3.4 ml water.
Hybridization of SureSelect custom Promoter and Region Capture libraries to Hi-C
libraries was carried out using Agilent SureSelectXT reagents and protocols. Post-
capture ampliﬁcation was carried out using six cycles of PCR from streptavidin
beads in multiple parallel reactions, then pooled and puriﬁed using SPRI beads.
Paired-end next generation sequencing. Two biological replicates for each of the
cell lines were prepared for each target capture. Sequencing was performed on
Illumina HiSeq 2500 generating 75 bp paired-end reads (Genomic Technologies
Core Facility in the Faculty of Life Sciences, the University of Manchester).
CASAVA software (v1.8.2, Illumina) was used to make base calls; reads failing
Illumina ﬁlters were removed before further analysis. Promoter Capture libraries
were each sequenced on one HiSeq lane and each Region Capture was sequenced
on 0.5 of a HiSeq lane. Sequences were output in FASTQ format, poor quality reads
truncated or removed as necessary, using Trimmomatic version 0.30 (ref. 25), and
subsequently mapped to the human reference genome (GRCh37/hg19) and ﬁltered
to remove experimental artefacts using the Hi-C User Pipeline (HiCUP, http://
www.bioinformatics.babraham.ac.uk/projects/hicup/). Off-target di-tags, where
neither end mapped to a targeted HindIII restriction fragment, were removed from
the ﬁnal data sets using a combination of BEDTools and command line tools. Full
details of the number and proportion of excluded di-tags are given in
Supplementary Table 3.
Analysis of Hi-C interaction peaks. Di-tags separated by o20 kb were removed
prior to analysis, as 3C data have shown a very high-interaction frequency within
this distance26. Di-tags were then assigned to one of the four categories of ligations
deﬁned in the study by Dryden et al.6 using custom scripts: (1) single baited, cis
interaction (o5Mb); (2) single baited cis interactions (45Mb); (3) double-baited cis
and (4) trans (either single or double baited). Signiﬁcant interactions for cis
interactions within 5Mb were determined using the ‘High resolution analysis of the
cis interaction peaks’ method described in the study by Dryden et al6. To correct for
experimental biases, the interactability of each fragment was determined.
Interactability is calculated from the interactions from a particular baited HindIII
restriction fragment to long-range, ‘trans’ fragments, under the assumption that
those represent random, background interactions and so should be similar in any
particular baited fragment. The resulting distribution is bimodal consisting of
stochastic noise (low trans counts) and genuine signal (high trans counts). A
truncated negative binomial distribution was ﬁtted to the distribution with the
negative binomial truncation point for interacting restriction fragments set at a count
of 3,000 and non-interacting set at 1,500 for the Promoter Capture and 600 for the
Region Capture due to differences in read depth. The 5% quantile point of the non-
truncated distribution was determined to provide the noise threshold. For both cell
lines in both captures, the noise threshold was determined to be 400 di-tags and
therefore all restriction fragments with fewer than 400 di-tags were ﬁltered out. A
negative binomial regression model was ﬁtted to the ﬁltered data correcting for the
interactability of the captured restriction fragment and interaction distance. For
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interactions, where both the target and baited region were captured (double-baited
interactions), we also accounted for the interactability of the other end.
We wanted to examine whether concordance between interactions called in the
Region and Promoter Capture experiments increased with decreasing FDR
thresholds. This is complicated because we can only deﬁne the set of interactions
that could have been observed in both experiments conditional on those that were
observed at a given FDR threshold in one experiment. We therefore decided to
normalize to those interactions called at an FDR threshold of 20% in the region
experiment and deﬁned the following enrichment parameter: X[i,j]¼P (called in
Region Capture at FDR i and in Promoter Capture at FDR j| called in Region
Capture at FDR 20%)/P(called in Region Capture at FDR i| called in Region
Capture at FDR 20%).
Interactions were considered statistically signiﬁcant after combining replicates
and ﬁltering on FDRr5%. Signiﬁcant Interactions were visualized in the WashU
Epigenome Browser (http://epigenomegateway.wustl.edu/browser/)27,28.
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